Our priority is to protect and aid the health and safety of our employees, our customers and their patients. That means ensuring our vital products are available when needed. It also means finding new and creative ways to support the frontline healthcare providers working tirelessly to address the COVID-19 pandemic.Learn More
At each post-Voraxaze® assessment time point, the median MTX concentration was <0.54 μmol/L, corresponding to a median reduction of ≥97% from pre-Voraxaze® measurements.2
Voraxaze® reduced plasma MTX concentrations by ≥97% within 15 minutes in all 22 treatment-evaluable patients.1
of patients taking Voraxaze® (20 of 22) achieved sustained reductions for up to 8 days1
of patients (10 of 22) achieved rapid and sustained clinically important reduction (RSCIR)1
Incidence of Grade 4 toxicity was significantly lower with early administration of Voraxaze®2
Incidence of mortality was significantly lower with early administration of Voraxaze®3
Patients can achieve clinically important reductions in plasma MTX concentrations within 15 minutes vs 5 to 11 days
Not every patient requires Voraxaze®, but experts have assembled recommendations to help guide treatment.
Explore the guidelines for the use and stocking of Voraxaze® so that you’re prepared in an emergency.